Merrie Mosedale

Merrie Mosedale

Auto-generated profile, based on publicly available information

Merrie Mosedale

Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill, Research Triangle Park, North Carolina 27709

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Cell Metabolism
Verified
Journal Article
Closed access
TKTimothy R. Koves
Timothy R. Koves
JUJohn R. Ussher
John R. Ussher
RNRobert C. Noland
Robert C. Noland
DSDorothy Slentz
Dorothy Slentz
MMMerrie Mosedale
Merrie Mosedale
DMDeborah M. Muoio
Deborah M. Muoio

9 November 2016 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MMM Mosedale
M Mosedale
PWPb Watkins
Pb Watkins

1 February 2013 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
TKTimothy R. Koves
Timothy R. Koves
LSLauren M. Sparks
Lauren M. Sparks
JKJ. P. Kovalik
J. P. Kovalik
MMMerrie Mosedale
Merrie Mosedale
RARamamani Arumugam
Ramamani Arumugam
DMDeborah M. Muoio
Deborah M. Muoio
Timothy R. Koves, Lauren M. Sparks, J. P. Kovalik, Merrie Mosedale, Ramamani Arumugam, Karen L. DeBalsi, Karen Everingham, Leigh Thorne, Esther Phielix, Ruth C. Meex, C. Lawrence Kien, Matthijs K. C. Hesselink, Patrick Schrauwen, Deborah M. Muoio

1 February 2015 in Food and Chemical Toxicology
Verified
Journal Article
Open access
RCRachel J. Church
Rachel J. Church
DGDaniel M. Gatti
Daniel M. Gatti
TUThomas J. Urban
Thomas J. Urban
NLNanye Long
Nanye Long
XYXi Yang
Xi Yang
AHAlison H. Harrill
Alison H. Harrill
Consumer use of herbal and dietary supplements has recently grown in the United States and, with increased use, reports of rare adverse reactions have emerged. One such supplement is green tea extract, containing the polyphenol epigallocatechin gallate (EGCG), which has been shown to be hepatotoxic at high doses in animal models. The Drug-Induced Liver Injury Network has identified multiple patients who have experienced liver injury ascribed to green tea extract consumption and the relationship to dose has not been straightforward, indicating that differences in sensitivity may contribute to the adverse response in susceptible people. The Diversity Outbred (DO), a genetically heterogeneous mouse population, provides a potential platform for study of interindividual toxicity responses to green tea extract. Within the DO population, an equal exposure to EGCG (50 mg/kg; daily for three days) was found to be tolerated in the majority of mice; however, a small fraction of the animals (16%; 43/272) exhibited severe hepatotoxicity (10-86.8% liver necrosis) that is analogous to the clinical cases. The data indicate that the DO mice may provide a platform for informing risk of rare, adverse reactions that may occur in consumer populations upon ingestion of concentrated herbal products.

21 September 2016 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
JWJeffrey L. Woodhead
Jeffrey L. Woodhead
WBWilliam J. Brock
William J. Brock
SRSharin E. Roth
Sharin E. Roth
SSSusan E. Shoaf
Susan E. Shoaf
KBKim L.R. Brouwer
Kim L.R. Brouwer
LSLisl K.M. Shoda
Lisl K.M. Shoda
Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD). No liver injury has been observed with tolvaptan treatment in healthy subjects and in non-ADPKD indications, but ADPKD clinical trials showed evidence of drug-induced liver injury (DILI). Although all DILI events resolved, additional monitoring in tolvaptan-treated ADPKD patients is required. In vitro assays identified alterations in bile acid disposition and inhibition of mitochondrial respiration as potential mechanisms underlying tolvaptan hepatotoxicity. This report details the application of DILIsym software to determine whether these mechanisms could account for the liver safety profile of tolvaptan observed in ADPKD clinical trials. DILIsym simulations included physiologically based pharmacokinetic estimates of hepatic exposure for tolvaptan and2 metabolites, and their effects on hepatocyte bile acid transporters and mitochondrial respiration. The frequency of predicted alanine aminotransferase (ALT) elevations, following simulated 90/30 mg split daily dosing, was 7.9% compared with clinical observations of 4.4% in ADPKD trials. Toxicity was multifactorial as inhibition of bile acid transporters and mitochondrial respiration contributed to the simulated DILI. Furthermore, simulation analysis identified both pre-treatment risk factors and on-treatment biomarkers predictive of simulated DILI. The simulations demonstrated that in vivo hepatic exposure to tolvaptan and the DM-4103 metabolite, combined with these 2 mechanisms of toxicity, were sufficient to account for the initiation of tolvaptan-mediated DILI. Identification of putative risk-factors and potential novel biomarkers provided insight for the development of mechanism-based tolvaptan risk-mitigation strategies.

2 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LNLeah M Norona
Leah M Norona
DNDeborah G Nguyen
Deborah G Nguyen
DGDavid A Gerber
David A Gerber
SPSharon C Presnell
Sharon C Presnell
MMMerrie Mosedale
Merrie Mosedale
PWPaul B Watkins
Paul B Watkins
Hepatic fibrosis develops from a series of complex interactions among resident and recruited cells making it a challenge to replicate using standard in vitro approaches. While studies have demonstrated the importance of macrophages in fibrogenesis, the role of Kupffer cells (KCs) in modulating the initial response remains elusive. Previous work demonstrated utility of 3D bioprinted liver to recapitulate basic fibrogenic features following treatment with fibrosis-associated agents. In the present study, culture conditions were modified to recapitulate a gradual accumulation of collagen within the tissues over an extended exposure timeframe. Under these conditions, KCs were added to the model to examine their impact on the injury/fibrogenic response following cytokine and drug stimuli. A 28-day exposure to 10 ng/mL TGF-β1 and 0.209 μM methotrexate (MTX) resulted in sustained LDH release which was attenuated when KCs were incorporated in the model. Assessment of miR-122 confirmed early hepatocyte injury in response to TGF-β1 that appeared delayed in the presence of KCs, whereas MTX-induced increases in miR-122 were observed when KCs were incorporated in the model. Although the collagen responses were mild under the conditions tested to mimic early fibrotic injury, a global reduction in cytokines was observed in the KC-modified tissue model following treatment. Furthermore, gene expression profiling suggests KCs have a significant impact on baseline tissue function over time and an important modulatory role dependent on the context of injury. Although the number of differentially expressed genes across treatments was comparable, pathway enrichment suggests distinct, KC- and time-dependent changes in the transcriptome for each agent. As such, the incorporation of KCs and impact on baseline tissue homeostasis may be important in recapitulating temporal dynamics of the fibrogenic response to different agents.